Edgewise Therapeutics, Inc. (EWTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put EWTX beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Report CIRRUS-HCM Part D 12-week data by end of Q2 2026: Data report delayed beyond Q2 2026.
View ThesisThis stock is volatile — it swings about 2% on a typical day and fell roughly 25% in its worst 12-month stretch.
View RiskEWTX's cardiovascular pipeline has to keep advancing to justify the price. The company is unprofitable, so growth is the only metric that matters. Revenue data is missing, so the growth trajectory is unverified. The latest quarter missed consensus estimates by 10.4%. We cannot anchor a clean multiple for EWTX right now. The price is roughly in line with the growth we forecast. The primary pillar is under pressure from a delayed data report. Our model puts the next-quarter miss probability near 39%. Peer multiples imply a price about 29% above where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. EWTX is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 13 analysts currently covering EWTX (as of Nov 2026).
Based on 4 Wall Street analysts offering 12-month price targets for EWTX in the last 4 months.
Continue this research
Compare EWTX with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EWTX Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put EWTX next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance cardiovascular pipeline with EDG-7500 and EDG-15400
Analyst upgrade signals positive view on pipeline progress.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $37.53
The last 12 months of price, then the range of analyst 12-month targets from today’s $37.53.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Advances: Advance cardiovascular pipeline with EDG-7500 and EDG-15400
Differentiated mechanism supports cardiovascular pipeline advancement.
